Medical Oncology Ⅲ



The Department of Medical Oncology Ⅲ of the First Affiliated Hospital of Zhejiang University School of Medicine was founded on November 7, 2014. As an emerging medical team focusing on comprehensive tumor diagnosis and treatment, our center’s work mainly includes day care chemotherapy for patients. We have CAR-T for hepatocellular cancer and gastric cancer as well as other cutting-edge cancer therapy technologies, cooperating with top oncology teams around the world, and participating multiple innovative new drug clinical trials for our patients who could not benefit from traditional treatment.

Academic status

Relying on the advantage platform of FAHZU, our center has gradually established a clinical and basic research system closely integrated with translational science. At present, we have received 6 projects funded by the national natural fund, 2 major science and technology project funded by the province, and several projects funded by the provincial level, including the provincial natural fund. We have published dozens of SCI papers, participated in the compilation of three books (people's health publishing house), participated in the compilation of five clinical guidelines and have four national invention patents. Participated in the construction of 2015 Zhejiang provincial supporting discipline "clinical medical genetic engineering", and participated in the construction of Zhejiang provincial precision health center (tumor) from 2018.

Research and Education achievements

Since 2018, there were over 6,000 patients with one-day chemotherapy were admitted per year, a year-on-year increase of more than 30%, fully demonstrating the advantages of diagnosis and treatment features and multidisciplinary comprehensive diagnosis and treatment with strong support from the surgical platform. Our department carries out CAR T, PD1/PDL-1 and other leading global research on the treatment of hepatobiliary and gastric cancer and participates in a number of domestic and international multicenter clinical research, including: Checkmate 459, Keynote 394, KN035, IM BRAVE150, AXEPT, etc. and keep close relationship with domestic and foreign top teams of diagnosis and treatment.

The research direction of our department are individualized diagnosis and treatment under the guidance of large database of genes, relationship between intestinal flora and tumors, cell immunotherapy including CAR T and molecular characteristics of peripheral blood and development of nanometer drugs and transmitters.

Our center has hosted 5 sessions national continuing education class of progress in perioperative comprehensive diagnosis and treatment of hepatobiliary and pancreatic tumors, and held 1-2 national and regional academic conferences on digestive system tumors every year. We regularly invite well-known experts at home and abroad to visit and communicate, and establish a good cooperative relationship with the world's top oncology team.

Characteristics of department

1. Multidisciplinary diagnosis and treatment in digestive system cancer. Characterized by one-day chemotherapy for hepato-bilio-pancreatic and gastrointestinal cancer;

2. Focus on the development of clinical translational diagnosis and treatment that includes precision drug use and immunotherapy, so as to provide more options for patients;

3. Focus on the basic research of immunotherapy and intestinal flora research. Continue to promote scientific research that can guide clinical practice, and continue to improve the leading academic position of our center in precision oncology area.